More precise understanding of the immune response against T-cell receptors (TCRs) is a prerequisite for successful TCR vaccination therapy of multiple sclerosis and other neurological autoimmune diseases. We conducted a detailed analysis of a paradigmatic anti-TCR response, using synthetic TCR peptides and highly purified recombinant TCR Vα and Vβ variable chains for the selection of CD4 ⍣ T-cell lines from a healthy volunteer. The target TCR (designated TCR HWBP-3 ) was obtained from HWBP-3, an autologous CD4 ⍣ T-cell line specific for myelin basic protein. The Vα and Vβ chains of TCR HWBP-3 were expressed in Escherichia coli and purified by Ni-chelate chromatography and SDS (sodium dodecyl sulphate) gel electrophoresis. Further, we synthesized a set of 13-to 22-mer peptides spanning the complementaritydetermining regions (CDR) 1, 2 and 3 and the framework regions (FR) of the α and β chains of TCR HWBP-3 . The TCR Keywords: autoimmune disease; immunotherapy; multiple sclerosis Abbreviations: CDR ϭ complementarity-determining region (of the T-cell receptor); FITC ϭ fluorescein isothiocyanate; FR ϭ framework region (of the T-cell receptor); HLA ϭ human leukocyte antigen; IFN ϭ interferon; IL ϭ interleukin; mAb ϭ monoclonal antibody; MBP ϭ myelin basic protein; MHC ϭ major histocompatibility complex; PBMC ϭ peripheral blood mononuclear cell; PMA ϭ phorbol myristate acetate; PPD ϭ purified protein derivative of tuberculin; SI ϭ stimulation index; TCL ϭ T-cell line; TCR ϭ T-cell receptor; TNF ϭ tumour neurosis factor
Introduction
Based on T-cell and T-cell receptor (TCR)-peptide vaccination experiments in animals (Ben-Nun and BenNun et al., 1981; Howell et al., 1989; Vandenbark et al., 1989) , clinical trials of TCR vaccination have recently been conducted in patients with multiple sclerosis (Medaer et al., 1995; Vandenbark et al., 1996a; Gold et al., 1997; Wilson © Oxford University Press 1998 peptides and proteins were then used to select a panel of TCR-specific CD4 ⍣ T-cell lines from donor HW. Several T-cell lines cross-reacted with a recombinant V chain and synthetic peptide. Cross-reactive immunogenic TCR epitopes were identified in the FR1 and CDR3 regions of the TCR HWBP-3 α chain and in the FR1, CDR1 and CDR2 regions of the TCR HWBP-3 β chain. The TCR proteins and peptides were recognized in the context of at least three different HLA-DR molecules [DR2a (DRB5*0101), DR2b (DRB1*1501) and DRB1*1401/DRB3*0202]. Notably, the majority of the TCR peptide-selected T-cell lines did not react with the full-length recombinant V chains, suggesting they recognize 'cryptic' determinants. Based on the diversity of the anti-TCR immune response, we suggest that candidate TCR peptides should be screened in vitro in functional experiments before they are clinically applied for TCR vaccination therapy. et al., 1997) . For example, in a double-blind placebocontrolled trial, patients with primary or secondary chronic progressive multiple sclerosis were vaccinated with short synthetic peptides of the TCR Vβ5.2 complementaritydetermining region (CDR) or placebo (Vandenbark et al., 1996a, b) . Although the immunological data obtained in the trial indicate that vaccination with TCR peptides increases the frequency of TCR peptide-specific regulatory cells, the trial did not demonstrate a convincing clinical benefit (reviewed in Antel et al., 1996; Hohlfeld, 1997) . This may not be surprising, considering how little is known about the molecular characteristics of the anti-TCR immune response, especially in humans.
The TCR is a heterodimer composed of one α and one β chain. Each chain contains a constant and a variable part, and each variable part contains relatively conserved regions [framework regions (FR) 1, 2 and 3] and hypervariable regions (CDR1, 2 and 3). The clonotypic CDR3 region is the most obvious candidate for recognition by strictly clonotype-specific regulatory T cells, but other regions of the TCR, including the FR, may also be involved in TCR regulatory circuits (Kumar et al., 1995) . It should be noted that, although much evidence has accumulated that TCR regulatory networks exist (e.g. Jerne, 1974; Lamb and Feldmann, 1982; Mohagheghpour et al., 1986; Lider et al., 1988; Sun et al., 1988; Cohen, 1992; Broeren et al., 1994; Breedveld et al., 1995; Kumar et al., 1995 Kumar et al., , 1996 Chunduru et al., 1996; Waisman et al., 1996) , as yet no detailed epitope analysis of human TCR α and β chains has been reported.
Using two synthetic peptides of a defined TCR Vβ chain, we have previously demonstrated that it is possible, in principle, to select TCR peptide-specific, major histocompatibility complex (MHC) class II-restricted CD4 ϩ T cells from the normal, unprimed human repertoire (SaruhanDireskeneli et al., 1993) . It has remained unknown, however, whether the self-determinants recognized by these TCRpeptide-specific T-cell lines (TCLs) arise during the processing of full-length TCR, and which of the different TCR framework and CDR regions of the α and β chain are recognized by anti-TCR TCLs.
In the present study we have taken a first step to help answer these questions. We have performed a detailed analysis of an anti-TCR response in the unprimed immune system of a healthy volunteer, using the following approach. We expressed and highly purified the full-length TCR Vα and Vβ chains of the well-characterized TCL HWBP-3, which was isolated from donor HW (Pette et al., 1990; Meinl et al., 1993) . HWBP-3 is specific for myelin basic protein (MBP), one of the candidate autoantigens thought to be involved in the pathogenesis of multiple sclerosis (Martin et al., 1992; Wekerle et al., 1994; Hafler et al., 1996; Hohlfeld, 1997) . Further, we synthesized a set of 13-to 22-mer peptides spanning CDR1, CDR2, CDR3 and the framework regions of the α and β chains of TCR . The different TCR peptides and proteins were then used to select a panel of TCR-specific CD4 ϩ TCLs from donor HW. The TCLs selected with TCR peptides were tested for cross-reactivity with the full-length recombinant Vα and β chains, and the TCLs selected with the recombinant TCR chains were tested for reactivity with the synthetic α-and β-chain peptides. Several anti-TCR TCLs clearly cross-reacted with both a synthetic peptide and the corresponding recombinant fulllength TCR chain. Specifically, cross-reactive immunogenic TCR epitopes were identified in the FR1 and CDR3 regions of the TCR HWBP-3 α chain and in the FR1, CDR1 and CDR2 regions of the TCR HWBP-3 β chain. Notably however, the majority of the TCLs selected with synthetic TCR peptides did not recognize the full-length recombinant TCR V chains, indicating that many peptide-selected TCLs are directed to cryptic determinants.
The results indicate that, without prior evaluation in vitro, short synthetic peptides are unlikely to be therapeutically effective. To improve the chance of successful TCR vaccination, candidate TCR synthetic peptides should be tested for cross-reactivity with the corresponding full-length recombinant chains in vitro in individual patients before therapy. Only cross-reactive synthetic peptides should be considered for therapy. Alternatively, longer recombinant TCR proteins should be used, either for protein-based (Kumar et al., 1997) or DNA-based (Waisman et al., 1996) TCR vaccination.
Method

Antigen-specific T-cell lines
The MBP-specific TCL HWBP-3 was isolated from the normal donor HW as described previously (Pette et al., 1990; Meinl et al., 1993) . HWBP-3 recognizes the MBP peptide 139-153 in the context of human leukocyte antigen (HLA) DRB5*0101 (the HLA-DR type of HW is as follows: DRB5*0101, DRB1*1501 and DRB1*1401/DRB3*0202). HWBP-3 expresses a Vα21/Vβ21.3 TCR (subsequently referred to as TCR ). The sequence is shown in Fig. 1 . A second MBP-specific TCL, HWBP-1.1, recognizes MBP peptide 108-131 in the context of HLA-DRB1*1401 and uses a Vα-non-21/Vβ7.2 TCR. A PPD (purified protein derivative of tuberculin)-and a tetanus toxoid-specific TCL (HWPPD-6 and HWTT-1.5) served as further controls. All TCL had the phenotype CD3 ϩ CD4 ϩ CD8 -TCRαβ ϩ . The MBP-specific and the tetanus toxoid-specific TCL secreted a TH0 (T-helper cell type 0)-like cytokine pattern. The PPDspecific TCL produced predominantly TH1 (T-helper cell type 1) cytokines.
Synthetic TCR peptides
An overlapping set of 13-to 22-mer peptides spanning the entire V, (D) and J sequences and 10 amino acids of the C region of the TCR HWBP-3 Vα and Vβ chains was synthesized ( Fig. 1) The panel of synthetic peptides included all three presumptive CDR regions (Fig. 1) . All peptides were synthesized using F-moc chemistry on a Peptide Synthesizer 431A (Applied Biosystems, Foster City, Calif., USA) and purified by reversed-phase chromatography on a PepRPC 15-µm column using a Pharmacia (Freiburg, Germany) FPLC system. Purity was confirmed by mass spectroscopy. 
Construction of plasmids for expression of V, (D), J-TCR α and β chains
Cloned cDNAs of the TCR α and β chains of clone HWBP-3 (Giegerich et al., 1992) were used as templates for polymerase chain reaction (PCR) amplification of the V(D)J-regions of the α and β chains. Eight amino-terminal residues of the α-chain constant region and 10 residues of the β-chain constant region were included. All PCR primers were extended for BglII restriction sites and for three irrelevant bases to facilitate later restriction digestion. The PCR primers were as follows: TCR α-chain: coding strand, 5Ј-GGAAGA-TCTCAGCAAGTTAAGCAAAATTCAC; complementary strand, 5Ј-GGAAGATCTGGCAGGGGTCAGGGTTCTG. TCR β-chain: coding strand, 5Ј-GGAAGATCTGCCCAGT-CTCCCAGATATAA; complementary strand: 5Ј-GGAAGAT-CTCTCGGGTGGGAACACGTTT.
The BglII-digested PCR product of the α chain was cloned into the BamHI site of the plasmid pQE12 (Qiagen, Düsseldorf, Germany). The BglII-digested PCR product of the β chain was cloned into pQE12, double-digested with BamHI and BglII. The recombinant proteins were extended at the N and C termini as shown in Fig. 1 (asterisks) . The sequences of both constructs were confirmed by full-length sequencing of the inserts.
Expression and purification of the recombinant TCR HWBP-3 Vα and Vβ chains
The transformed Escherichia coli strain M15 (Qiagen, Hilden, Germany) was induced at an optical density of 0.5 at 600 nm with 1 mM isopropyl thiogalactoside and harvested after 4 h by centrifugation. Bacteria pellets from 12 l of culture were resuspended in 300 ml distilled water and pulsesonicated on ice for 1.5 h using a Branson Sonifier 450. After centrifugation at 43 000 g for 30 min, the pellet was resuspended in 300 ml of 6 M urea, 0.5 M NaCl, 100 mM sodium acetate buffer, pH 8, and pulse-sonicated on ice for 1.5 h. After centrifugation (43 000 g, 30 min) the supernatant was applied to a 10-ml Chelating Sepharose Fast Flow column (Pharmacia, Freiburg, Germany) previously loaded with NiCl 2 and then equilibrated in 6 M urea, 0.5 M NaCl, 100 mM sodium acetate buffer, pH 8. The column was washed with 100 ml of 6 M urea, 0.5 M NaCl, 100 mM sodium acetate buffer, pH 6, and eluted by a pH step gradient (pH 5.5, 5.2, 4.5, 3.0) . Fractions eluted at pH 5.2 and 4.5 were neutralized, dialysed against distilled water and lyophilized. Twenty milligrams of protein was subjected to preparative SDS-PAGE (polyacrylamide gel electrophoresis) using 2 ϫ 200 ϫ 200 mm 20% gels and electroeluted from the gel with a Bio-Rad 422 Electroeluter (Bio-Rad, Munich, Germany). The proteins were precipitated and SDS was removed according to Wessel and Flügge (1984) . Final incubation in methanol and drying in a laminar air-flow served as sterilization steps prior to use in cell culture. Both TCR chains were insoluble in water and were therefore sonicated intensely to yield a fine suspension. Purity of the proteins was confirmed using silver-stained SDS gels. To confirm the identity of the purified proteins, the sequence of the first 10 N-terminal amino acids was determined.
Isolation of TCLs specific for TCR HWBP-3
Peripheral blood mononuclear cells (PBMC) were isolated from donor HW by density gradient centrifugation (Lymphoprep, Nycomed, Oslo, Norway). Antigen-specific CD4 ϩ TCL were established using a modified 'split-well' protocol (Pette et al., 1990; Meinl et al., 1993) . Briefly, 2 ϫ 10 5 PBMC were seeded in 200 µl medium (RPMI supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 5% pooled human AB serum) in the presence of 30 µg/ml recombinant TCR α-or β-chain or 10 µg/ml TCR peptides in 96-well round bottom microtitre plates (Nunc A/S Roskilde, Denmark). The cells were fed with 5 U/ml recombinant human interleukin-2 (provided by Hoffmann La Roche, Basel, Switzerland) every 3-7 days. After 14 days the contents of each well were split between two wells. Antigen was added to one of the wells, and 10 5 irradiated autologous PBMC were added to both wells. The cultures were scanned microscopically for antigen-specific proliferation. Specifically responding populations were selected for further expansion and restimulated every 7-14 days.
Epitope specificity of TCLs specific for TCR HWBP-3
Specificity for the recombinant TCR HWBP-3 chains and/or synthetic TCR HWBP-3 peptides was assessed in proliferation assays. Duplicate or triplicate wells containing 3 ϫ 10 4 antigen-specific T cells and 10 5 irradiated (5000 rad) autologous PBMC were incubated in the presence or absence of recombinant TCR fragments, synthetic TCR peptides or recombinant control protein (irrelevant recombinant TCR chain or recombinant S100β of comparable molecular weight prepared with the same expression and purification system as the recombinant TCR proteins). After 48 h, 0.22 µCi [ 3 H]thymidine (Amersham, Braunschweig, Germany) was added to each well. Cells were harvested 18 h later. Uptake of [ 3 H]thymidine was measured with a gas scintillation counting system (Matrix TM 96, Direct Beta Counter, Packard, Germany). The criteria for specificity are detailed in the legend to Table 1 .
Membrane phenotype and TCR expression of TCR HWBP-3 -specific TCL
T cells were stained by indirect immunofluorescence with a series of monoclonal antibodies (mAb) including OKT 4 
Cytokine production
In order to establish the cytokine secretion profile of the anti-TCR HWBP-3 TCLs, the following cytokines were measured in culture supernatants by sandwich ELISA (enzyme-linked immunosorbent assay): interferon (IFN)-γ, tumour necrosis factors (TNF) α and β, and interleukins (IL) 4 and 10. Briefly, 96-well flat-bottomed plates (Nunc A/S) were coated with anti-cytokine mAb. Non-specific binding was blocked by incubation with PBS containing 1% bovine serum albumin. Supernatants or recombinant cytokine were added for 1 h. Subsequently, the wells were incubated with a biotinylated second antibody, followed by streptavidin-coupled peroxidase and TMB (3,3Ј-5,5Ј-tetramethylbenzidine) substrate (Pierce, Rockford, Ill., USA). The reaction was stopped with H 2 O 2 and extinction-read at the appropriate wavelength. In addition, the cytokine profile of some anti-TCR HWBP-3 TCLs was confirmed by intracellular flow cytometry staining. Briefly, 10 5 T cells were stimulated with 5 µg/ml PMA (Sigma Chemical Co., St Louis, USA) and 250 ng/ml ionomycin (Sigma) in the presence of 2 µM monensin (Sigma). After 6 h cells were harvested and fixed for 20 min on ice using 4% paraformaldehyde. Then the cells were stained with anti-IL-4-phycoerythrin and anti-IFN-γ-FITC (PharMingen, San Diego, Calif., USA) diluted in 0.1% saponin permeabilization solution on ice in the dark. After 30 min the cells were washed in PBS containing 1% BSA and analysed by flow cytometry (Becton Dickinson).
Cytotoxicity assay
Cytotoxicity of anti-TCR HWBP-3 TCLs against antigen-pulsed PBMC or HWBP-3 cells was measured with a chromium release assay. Briefly, target cells were labelled with 51 Cr (100 µCi/1 ϫ 10 6 cells) in a total volume of 1 ml complete medium for 2 h at 37°C. After washing three times with culture medium, the labelled target cells were incubated for an additional 2 h in flat-bottom microtitre wells (5 ϫ 10 4 and 1 ϫ 10 5 /200 µl). Thereafter cells were washed again, and anti-TCR HWBP-3 TCLs were added to the PBMC in the presence of antigen (recombinant TCR HWBP-3 α and β chain or synthetic TCR HWBP-3 peptide) or to HWBP-3 target cells in different effector/target ratios (0.5 : 1, 1 : 1, 2 : 1, 5 : 1) and incubated for up to 16 h. Release of 51 Cr was measured in a γ-counter (Canberra-Packard GmbH, Dreieich, Germany) and calculated according to the formula: cytotoxicity ϭ 100 ϫ (r -b)/(m -b), where r is mean measured release, b is mean background release, and m is mean maximal release. MBP-specific TCLs from the same donor served as positive controls in these cytotoxicity experiments.
MHC restriction
MHC restriction of the anti-TCR HWBP-3 TCL was determined using either HLA-DR-transfected mouse L cells or irradiated MHC-typed PBMC as antigen-presenting cells. Transfected L cells expressing the DR2a (DRA/DRB5*0101) or DR2b (DRA/DRB1*1501) molecule were grown to confluence, recovered by trypsination and treated with mitomycin C as described previously . L cells transfected with thymidine kinase (LTK) served as a control. MHC restriction was further screened using irradiated autologous DR2/w6(w52) and allogenic DR5/w6(w52) PBMC in the absence or presence of anti-HLA-DR mAb (L243; American Type Culture Collection; diluted 1 : 4).
Presentation of TCR by MBP-specific TCL
The presentation of exogenous recombinant TCR HWBP-3 and synthetic TCR HWBP-3 peptides by the MBP-specific TCLs HWBP-3 and HWBP-1.1 was investigated as follows. HWBP-3 and HWBP-1.1 cells and, for comparison, autologous PBMC were irradiated with 4500 rad and pulsed with synthetic TCR peptide (15 µg/ml; 10 5 cells per well) or recombinant TCR chains (30 µg/ml), before anti-TCR HWBP-3 TCL (5 ϫ 10 4 cells per well) were added. After 48 h, 0.22 µCi Presentation of endogenous (naturally processed) TCR HWBP-3 was assessed in several different experiments that were all negative. First, anti-TCR HWBP-3 TCLs were stimulated with dissociated HWBP-3 cells and autologous macrophages in the presence or absence of pan anti-TCRαβ antibody. Macrophages were isolated by incubating PBMC in culture flasks at 10 ϫ 10 6 cells in 10 ml culture medium for 1 h. After washing with PBS, adherent macrophages were removed with a cell scraper, plated in round-bottomed microwells at a density of 5 ϫ 10 4 cells per well, and incubated with strongly irradiated (20 000 rad) HWBP-3 or control HWBP-1.1 cells in the presence or absence of 5 µg/ ml pan anti-TCRαβ antibody (Immunotech). After 24 h, anti-TCR HWBP-3 TCLs were added and proliferation was measured as described.
Secondly, anti-TCR HWBP-3 TCLs were stimulated with autologous macrophages and HWBP-3 derived TCR-coated Dynabeads. Briefly, sheep anti-mouse antibody-coupled Dynabeads (4.5 µm; Dynal, Hamburg, Germany) were first incubated with anti-CD3 (OKT 3) antibody and then with a HWBP-3 cell lysate in 1% Digitonin (Sigma) for 2 h (Samelson et al., 1985) . After extensive washing, 10 µl of the Dynabead suspension was added to macrophages. After 24 h, anti-TCR HWBP-3 TCLs were added and proliferation was measured as described.
Thirdly, to assess the direct presentation of naturally processed TCR HWBP-3 by HWBP-3 in the absence of additional antigen-presenting cells, anti-TCR HWBP-3 TCLs (5 ϫ 10 4 per well) were incubated with irradiated (4500 rad) HWBP-3 or control HWBP-1.1 (7 ϫ 10 4 cells per microwell; 2-7 days after restimulation with MBP or phytohaemag- glutinin). After 48 h, proliferation, cytotoxicity and IFN-γ secretion were measured as described.
Fourthly, to detect stimulatory or suppressive effects of anti-TCR HWBP-3 TCLs on HWBP-3, irradiated (4500 rad) anti-TCR HWBP-3 TCLs (5 ϫ 10 4 per well) were added to HWBP-3 (5 ϫ 10 4 cells per well) stimulated with MBP (30 µg/ml) plus irradiated (4500 rad) autologous PBMC (10 5 cells per well). After 48 h, 0.22 µCi [ 3 H]thymidine was added to each well. Thymidine uptake was measured as described. Figure 2 shows SDS gels with recombinant TCR HWBP-3 α chains (A) and β chains (B) of increasing purity. The first two lanes show total lysates of TCR-transfected bacteria before (lane 1) and after (lane 2) induction. The strong additional bands in lane 2 migrating with apparent molecular mass of~15 kDa represent the recombinant TCR proteins. Lane 3 shows the TCR α (A) and β (B) chains after purification on nitrilo-tri-acetic acid-agarose columns. Both chains are still contaminated with proteins migrating at 25 kDa. The chains were therefore subjected to preparative SDS gel electrophoresis and electroeluted from the gels. No contaminating proteins are detectable in these final preparations (lanes 4; Fig. 2 ). After removal of SDS this material was used for T-cell stimulation.
Results
Expression and purification of recombinant TCR α and β chains
Epitope specificity of anti-TCR HWBP-3 T cells stimulated with full-length rTCR HWBP-3 Vα and Vβ chains
A total of four TCLs were selected with the rTCR HWBP-3 α chain, and 21 TCLs with the rTCR HWBP-3 β chain. Some of these TCLs cross-reacted with one (and only one) of the synthetic peptides (Table 1) . Two of the TCLs selected with rTCR α chain cross-reacted with a FR1 peptide (Table 1A and Fig. 3A) . Of the TCLs selected with the rTCR HWBP-3 β chain, two cross-reacted with the CDR2 region peptides, two with the CDR1 region peptides, and two with a FR1 region peptide (Table 1B and Fig. 3B ).
Epitope specificity of anti-TCR HWBP-3 T cells stimulated with synthetic peptides
Overlapping TCR HWBP-3 peptides were grouped into six peptide pools, corresponding to the three CDR regions and three V framework regions for each TCR HWBP-3 chain (Fig. 1) . The TCR HWBP-3 peptide pools were used in parallel experiments to select anti-TCR HWBP-3 TCLs.
Twenty-two TCLs were selected with TCR HWBP-3 α chain peptides (Table 2A ) and three TCLs with synthetic TCR HWBP-3 β chain peptides (Table 2B) . Of the TCLs selected with the α chain peptides, 17 were selected with the α chain CDR3 region peptides and five with the FR3 peptides (Table 2A) . Five of the TCLs generated with the CDR3 region peptides but none of the other TCLs cross-reacted with the full-length recombinant Vα chain (Table 2A and Fig. 3C ). Of the three TCLs selected with β chain peptides, two were selected with the β chain FR1 peptide, and one with the FR3 peptides ( Table 2B ). None of these TCLs cross-reacted with the recombinant β chain (Table 2B ). The peptide-selected TCLs not reacting with the recombinant TCR chains apparently recognize 'cryptic' epitopes.
Surface phenotype, MHC restriction and TCR usage of anti-TCR HWBP-3 TCLs
Like most other TCLs selected with the split-well cloning technique, anti-TCR HWBP-3 TCLs displayed a CD3 ϩ CD4 ϩ CD8 -phenotype. Anti-TCR HWBP-3 TCLs were further analysed for MHC restriction and TCR usage. MHC restriction was established for eight TCL: four TCLs were restricted by DR2a(DRB5*0101), one by DR2b (DRB1*1501), and three by DR14/DRw52 (DRB1*1401/ DRB3*0202). Thus, at least three DR molecules expressed by donor HW (DR2a, DR2b, DRw6/DRw52) present TCR HWBP-3 epitopes. Analysis of TCR usage by flow cytometry analysis and reverse transcription-PCR did not provide evidence for predominant TCR usage by anti-TCR HWBP-3 TCL (data not shown).
Cytokine profile of anti-TCR HWBP-3 TCLs
To assess the cytokine secretion profile of anti-TCR TCL in comparison with autologous TH1 and TH0 TCL specific for other antigens, we measured the cytokines IFN-γ, TNF-α, TNF-β, IL-4 and IL-10 in culture supernatants. Sixteen of the TCLs selected with the rTCR chains produced high amounts of the TH1 cytokines IFN-γ (mean concentration in the supernatant, 22 874 pg/ml), TNF-β (1689 pg/ml) and TNF-α (2841 pg/ml) but little IL-4 (33 pg/ml) after stimulation with rTCR HWBP-3 (not shown). Most anti-TCR HWBP-3 TCLs also produced significant amounts of IL-10 (3982 pg/ml). The TH1 profile of our anti-TCR TCLs was confirmed by intracellular double staining for IFN-γ and IL-4. A dot plot of the flow cytometric analysis of a representative TCL is shown in Fig. 4 . The TCLs selected with TCR peptides produced much smaller amounts of cytokines than the TCLs selected with the recombinant TCR chains (data not shown).
Lack of cytotoxicity of anti-TCR TCLs
To assess the cytotoxic potential of anti-TCR HWBP-3 TCLs, effector cells were incubated with rTCR HWBP-3 -pulsed or TCR peptide-pulsed autologous PBMC or HWBP-3 TCLs as targets. Cytotoxicity was assessed by 51 Cr release or microscopic observation. No cytotoxic activity was detected (18 experiments, 10 TCLs tested; data not shown). In contrast, MBP-specific TCLs from the same donor (HW) were clearly cytotoxic (50% 51 Cr release at the effector:target ratio of 8 : 1).
Presentation of exogenous TCR peptides by autologous HWBP3
To assess the antigen-presenting capacity of HWBP-3, we compared the functional capacity of PBMC (Fig. 5A ) and HWBP-3 (Fig. 5B) to present either exogenous TCR HWBP-3 peptides (left) or rTCR HWBP-3 chains (right) to the anti-TCR HWBP-3 TCLs. PBMC presented both TCR peptide and rTCR HWBP-3 chain (Fig. 5A ). Presentation could be blocked with anti-MHC class II mAb. By comparison, HWBP-3 presented only synthetic peptide but was unable to present exogenous rTCR (Fig. 5B ).
Lack of presentation of endogenous TCR to anti-TCR HWBP-3
In a series of experiments, we found no evidence for recognition of endogenous TCR HWBP-3 by anti-TCR TCLs. Autologous macrophages pulsed with HWBP-3 or HWBP-3 lysates, in the presence or absence of pan anti-TCR mAb, did not induce detectable proliferation of anti-TCR HWBP-3 TCL (see Method; data not shown). In the presence of irradiated HWBP-3, anti-TCR TCLs showed increased proliferation and IFN-γ production. However, this effect was antigen-non-specific, since irrelevant (PPD-specific) TCLs also produced increased amounts of IFN-γ in the presence of irradiated HWBP-3 (not shown). Furthermore, we did not detect reproducible suppressive or stimulatory effects of anti-TCR TCLs on the antigen-induced proliferation of HWBP-3.
Discussion
Using synthetic TCR peptides and highly purified recombinant TCR Vα and Vβ chains, we undertook a detailed analysis of a human anti-TCR response in a healthy volunteer (HW). The target TCR, TCR HWBP-3 , is specific for human myelin basic protein (MBP) and is expressed by HWBP-3, a well-characterized CD4 ϩ TCL isolated from the same donor (Pette et al., 1990; Meinl et al., 1993) . We demonstrate that immunogenic TCR self-determinants are generated during the processing of full-length recombinant TCR Vα and β chains. Specifically, epitopes recognized by autologous CD4 ϩ TCR-specific TCLs were identified in the CDR3 and FR1 region of the α chain, and in the CDR1, CDR2 and FR1 region of the β chain of TCR . The results suggest that the human TCR α and β chains contain multiple self-epitopes that are generated during the processing of full-length TCR proteins, at least in vitro. On the other hand, many TCLs Table 1B ). After stimulation, the majority of cells express IFN-γ but little or no interleukin-4.
selected with synthetic TCR peptides did not react with fulllength TCR proteins, indicating that they recognize cryptic determinants. Our detailed analysis of an anti-TCR immune response had to be restricted to a single normal subject not only because of the complexity of the approach (which required the cloning and cellular characterization of MBP-specific T cells, recombinant expression and high purification of both chains of the MBP-specific TCR, and the detailed characterization of a large panel of TCR-specific TCLs), but also for logistic reasons (requiring continual co-operation, many blood donations for more than 2 years, and the absence of immunosuppressive therapy). However, this does not limit the validity of our main conclusions that the human anti-TCR immune response is extremely diverse and that the majority of TCLs selected with synthetic TCR peptides react to cryptic epitopes.
We have previously shown that self-TCR peptide-specific TCLs are represented in the normal human repertoire . However, it is still unknown whether and to what extent the epitopes recognized by TCR peptide-specific TCLs are generated during the processing of full-length TCR protein. Since endogenous TCR proteins cannot be purified in sufficient amounts, we expressed the Vα and β chain of HWBP-3 in E. coli. Selection of antigen-specific human TCL with recombinant proteins is notoriously difficult, because even small amounts of contaminating bacterial protein will evoke a vigorous response. Therefore, high purity of the recombinant protein is essential. After a series of efficient purification steps including Ni-chelate chromatography and SDS-PAGE, our recombinant TCR proteins were Ͼ99% pure. However, even these highly purified recombinant TCR proteins stimulated a detectable response against bacterial proteins. Definite proof of the specificity of the TCLs selected with recombinant TCR was provided by a cross-response to one of the synthetic peptides, which was observed with two of seven TCLs selected with rTCR Vα and six of 22 TCLs selected with rTCR Vβ. The other TCLs presumably react against epitopes not represented in our TCR peptide panel.
As expected, none of the TCLs that were selected with synthetic peptides reacted with recombinant control proteins. However, five of 25 peptide-selected TCLs cross-reacted with the appropriate full-length Vα or β chain, demonstrating that immunogenic self-epitopes are generated during the processing of full-length TCR HWBP-3 proteins. On the other hand, it is equally notable that the majority of the peptideselected TCLs did not react with full-length TCR protein, suggesting that they recognize 'cryptic' epitopes. This observation has an interesting parallel in another recent study in which human TCLs selected with a full-length recombinant antigen were systematically compared with TCLs selected with short synthetic peptides (Matsuo et al., 1995) . The authors demonstrated that TCLs selected with short synthetic peptides of the α chain of the human acetylcholine receptor did not react with the full-length recombinant acetylcholine receptor α-subunit protein. They concluded that, in their system, TCLs selected with synthetic peptides react mostly to 'cryptic' epitopes not generated during the natural processing of full-length acetylcholine receptor (Matsuo et al., 1995; Hawke et al., 1996) .
We have identified multiple epitopes in different regions of the TCR Vα and β chain, including the CDR and FR regions. It should be noted, however, that our relatively small sample does not allow conclusions as to the relative immunogenicity of the different TCR regions. In addition to epitope heterogeneity, further complexity of the anti-TCR immune response became apparent at the level of MHC restriction. Three HLA-DR molecules expressed by donor HW (DR2a(DRB5*0101), DR2b(DRB1*1501) and DRw14/ w52 (DRB1*1401/DRB3*0202) were identified as restriction elements for at least one anti-TCR TCL.
The anti-TCR TCLs showed a similar profile of cytokine secretion. They produced the TH1 cytokines IFN-γ, TNF-α and TNF-β, but little IL-4. In addition, most TCLs secreted significant amounts of IL-10, so that they can be classified as TH1/TH0 (Romagnani, 1994) . There was no indication that the epitope fine specificity (e.g. FR or CDR specificity) had an influence on the cytokine profile.
Our attempts to demonstrate the recognition of endogenous TCR , either on the surface of HWBP-3 itself or after processing by autologous macrophages, yielded negative results. This was clearly not due to a principal failure of HWBP-3 to act as antigen-presenting cells, since HWBP-3 was capable of presenting exogenous TCR peptides to anti-TCR TCLs, in line with other reports that human TCLs can act as functional antigen-presenting cells (LaSalle et al., 1991; Pichler and Wyss-Coray, 1994) . Interestingly, however, full-length TCR proteins were presented only by macrophages, not by HWBP-3, consistent with previous observations that the capacity of T cells to take up large proteins is limited (Lanzavecchia et al., 1988) . Direct proof that human T cells expose MHC-bound TCR self-peptides on their surface is still lacking, but it is reasonable to assume that TCRs are processed and presented like other self-proteins (Kourilsky et al., 1987; Chicz and Urban, 1994; Germain, 1994; Rammensee, 1995) . Autologous macrophages, pulsed with HWBP-3 lysates in the presence or absence of pan anti-TCR, also did not detectably stimulate our anti-TCR TCLs. Possible reasons include insufficient amounts of TCR peptides generated during processing and the lack of sensitivity of our assays (which included proliferation, IFN-γ production and cytotoxicity assays).
TCR network concepts form the basis for treatment strategies in experimental models and human autoimmune diseases. Regulatory responses capable of protecting animals from autoimmunity can be induced by vaccination with disease-causing, MBP-reactive CD4 ϩ T cells or, as has been found more recently, by immunization with TCR peptides from the CDR2 or FR3 region of the Vβ chain, or the CDR3 region of the Vα chain of encephalitogenic T cells (BenNun et al., 1981; Howell et al., 1989; Vandenbark et al., 1989; Kumar et al., 1995) . Very recently, two clinical trials of TCR vaccination in multiple sclerosis have been reported (Gold et al., 1997; Vandenbark et al., 1996a; Wilson et al., 1997) . In a double-blind placebo-controlled trial, 23 HLA-DR2-positive patients with primary or secondary chronic progressive multiple sclerosis were vaccinated with one of two TCR Vβ5.2 CDR2-region synthetic peptides or placebo (Vandenbark et al., 1996a) . In another trial, 10 patients were immunized with two different doses of a TCR Vβ6 CDR2-region synthetic peptide (Gold et al., 1997; Wilson et al., 1997) . Clinical efficacy was not demonstrated in these trials.
What is the rationale for TCR vaccination therapy? It is assumed that activated human T cells, which are known to express both MHC class I and class II antigens on their surface, display MHC-associated peptides of their own clonotypic TCRs (Fig. 6 ). These 'self peptides' would be generated during the normal protein turnover of endogenously produced TCRs. In addition, TCR proteins would be taken up from degenerating T cells by professional antigen-presenting cells, such as macrophages, processed and displayed on the macrophage surface in MHC class II-bound form (Fig. 6) . It is further assumed that these TCR-derived peptides displayed on T cells and macrophages can be recognized by TCRspecific ('anti-TCR') regulatory T cells. When activated, the regulatory T cells secrete inhibitory cytokines or kill the target T cell, thereby reducing the inflammatory activity in CNS lesions (reviewed in Antel et al., 1996; Vandenbark et al., 1996b; Hohlfeld, 1997) . By means of vaccination with the relevant TCR peptides, these naturally occurring regulatory mechanism should be strengthened.
The most obvious obstacles for the TCR vaccination approach include the following (discussed in Antel et al., 1996; Vandenbark et al., 1996b; Hohlfeld, 1997) . First, as shown in previous studies, the human T cell response against MBP is much more heterogeneous than the Vβ8.2-dominated response in the Lewis rat and PL/J mouse (Martin et al., 1992; Hohlfeld et al., 1995; Richert et al., 1995; Hafler et al., 1996) . Secondly, there is now growing evidence that many other myelin and even non-myelin autoantigens are encephalitogenic, so that MBP cannot be considered the only candidate autoantigen in multiple sclerosis (Wekerle et al., 1994) . However, as is often emphasized by proponents of TCR vaccination, the heterogeneity of the T-cell response against various CNS autoantigen(s) is not necessarily an unsurmountable obstacle: at least theoretically, a few TCRspecific TCLs could inhibit other TCLs specific for different epitopes of MBP or even other CNS autoantigens ('bystander suppression'; reviewed by Steinman, 1996) .
Our present study adds an additional level of complexity to the TCR vaccination approach. Our data suggest that the T-cell response even against a single MBP-specific TCR is heterogeneous. Several different TCR epitopes are recognized on the Vα and β chains, and several distinct MHC molecules function as restriction elements. Most notably, many of the TCLs selected with synthetic TCR peptides did not react with the corresponding full-length TCR V chain, suggesting that they recognize 'cryptic' determinants. It should also be noted, however, that our data do not allow us to quantify the relative heterogeneity of 'real' versus 'cryptic' TCR epitopes.
Based on our observations, it must be assumed that clinical trials relying on immunization with short synthetic TCR peptides are likely to be ineffective unless the candidate peptides are tested for cross-reactivity with the corresponding full-length recombinant chains in vitro in individual patients to identify cross-reactive peptides. Clearly, this by no means guarantees success, but seems to be a reasonable criterion for the selection of candidate synthetic peptides. Alternatively, and perhaps preferably, longer recombinant TCR proteins should be considered for therapy, either for protein-based (Kumar et al., 1997) or DNA-based (Waisman et al., 1996) TCR vaccination.
